Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:58 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 11,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Recruiting No phase listed Observational

Quantifying Radiation Induced Vaginal Stenosis

NCT05002751
View directory record Official record
Conditions
Vaginal Stricture, Vaginal Stenosis
Interventions
UCSD Vaginal Dilator Questionnaire, EORTC Sexual Health Questionnaire
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Nov 1, 2026, 6:58 PM EST
Active, not recruiting Phase 1 Interventional

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

NCT04047251
View directory record Official record
Conditions
Advanced Solid Tumors, Merkel Cell Carcinoma
Interventions
FF-10850 Topotecan Liposome Injection
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Not yet recruiting No phase listed Observational

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

NCT07893223
View directory record Official record
Conditions
Biomarkers, Acute Kidney Injury, Sepsis
Interventions
Not listed
Lead sponsor
Nutromics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 2 Interventional Results available

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

NCT01446159
View directory record Official record
Conditions
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions
MEDI-573, Aromatase Inhibitor
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
34
States / cities
Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Nov 1, 2026, 6:58 PM EST
Terminated Phase 1 Interventional

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

NCT04978779
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
Interventions
VIP152, BTKi
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Cincinnati, Ohio • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate Severe Hepatic Impairment on Dacomitinib PK

NCT03865446
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 1, 2026, 6:58 PM EST
Recruiting No phase listed Observational

Biological Sex and CTEPH-related RV Dysfunction and Recovery (BIOSPHeRe)

NCT06105242
View directory record Official record
Conditions
CTEPH
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Nov 1, 2026, 6:58 PM EST
Completed No phase listed Observational

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

NCT06854341
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00601094
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous dendritic cell-adenovirus CCL21 vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 1, 2026, 6:58 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Individualized Assessment and Treatment for Alcoholism II

NCT03233802
View directory record Official record
Conditions
Alcoholism
Interventions
Individualized Assess & Treatment (IATP), Packaged Cognitive-Behavioral (PCBT), Case Management (CaseM)
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569
View directory record Official record
Conditions
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
Interventions
ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Completed No phase listed Observational

Evaluation of a Symptom and Needs Assessment for Patients With Cancer

NCT04014751
View directory record Official record
Conditions
Cancer
Interventions
Symptom Monitoring Intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Nov 1, 2026, 6:58 PM EST
Completed No phase listed Observational

HIV Resistance and Treatment Strategies

NCT00581802
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Nov 1, 2026, 6:58 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals

NCT04449653
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Progentec Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Nov 1, 2026, 6:58 PM EST
Active, not recruiting Phase 1 Interventional

IBRX-042 In Participants With HPV-Associated Tumors

NCT05976828
View directory record Official record
Conditions
HPV-Related Carcinoma
Interventions
IBRX-042
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
2
States / cities
El Segundo, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Not yet recruiting No phase listed Observational

Prospective Ultrasound Data Collection Study for AI-Based Detection of Breast Biopsy Markers

NCT07427407
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Ultrasound Imaging With Investigational AI Software
Device
Lead sponsor
AURA Health Technologies
Industry
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

NCT03650400
View directory record Official record
Conditions
Asthma
Interventions
Fevipiprant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Minneapolis, Minnesota • Columbia, Missouri • Tulsa, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

NCT04117711
View directory record Official record
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Nov 1, 2026, 6:58 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Nov 1, 2026, 6:58 PM EST
Completed No phase listed Observational

Robotic-assisted Laparoscopic Sacrocolpopexy

NCT00581334
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Robotic-assisted laparoscopic sacrocolpopexy, Open sacrocolpopexy
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 1, 2026, 6:58 PM EST
Active, not recruiting No phase listed Observational

Postpartum Home Visiting (HEART at Home)

NCT07833904
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy (HDP)
Interventions
HEART at Home
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 1, 2026, 6:58 PM EST